Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
7d11p708cmAbWNGy
